TEGA is developing bioengineered heparin as an alternative to the current supply of heparin, 100% of which comes from pig intestines intestines and 80% of which comes from slaughterhouses in China. TEGA is also developing conjugates that enhanced the delivery of enzyme replacement therapies to the brain for Lysosomal Storage Disorders